Tau splicing and the intricacies of dementia

Journal of Cellular Physiology

Volumn 227, Issue 3, 2012, Pages 1220-1225

  Andreadis, Athena ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; CHROMOSOME 17Q; CYTOSKELETON; DEGENERATIVE DISEASE; DEMENTIA; EXON; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MICROTUBULE; MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; NERVE CELL; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; RNA SPLICING; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM;

ALTERNATIVE SPLICING; BASE SEQUENCE; DEMENTIA; HUMANS; MOLECULAR SEQUENCE DATA; NERVE DEGENERATION; TAU PROTEINS; TAUOPATHIES;

EID: 80054990959     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22842     Document Type: Short Survey

References (49)

1. Andreadis A. 2005. Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochem Biophys Acta 1739: 91-103.
2. Andreadis A. 2006. Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog Mol Subcell Biol 44: 89-107.
3. Ashe KH, Zahs KR. 2010. Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645.
4. Bishop NA, Lu T, Yankner BA. 2010. Neural mechanisms of ageing and cognitive decline. Nature 464: 529-535.
5. Brandt R, Hundelt M, Shahani N. 2005. Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim Biophys Acta 1739: 331-354.
6. Caffrey TM, Wade-Martins R. 2007. Functional MAPT haplotypes: Bridging the gap between genotype and neuropathology. Neurobiol Dis 27: 1-10.
7. Conrad C, Vianna C, Freeman M, Davies P. 2002. A polymorphic gene nested within an intron of the tau gene: Implications for Alzheimer's disease. Proc Natl Acad Sci USA 99: 7751-7756.
8. Conrad C, Vianna C, Schultz C, Thal DR, Ghebremedhin E, Lenz J, Braak H, Davies P. 2004. Molecular evolution and genetics of the saitohin gene and tau haplotype in Alzheimer's disease and argyrophilic grain disease. J Neurochem 89: 179-188.
9. Conrad C, Zhu J, Conrad C, Schoenfeld D, Fang Z, Ingelsson M, Stamm S, Church G, Hyman BT. 2007. Single molecule profiling of tau gene expression in Alzheimer's disease. J Neurochem 103: 1228-1236.
10. Denk F, Wade-Martins R. 2009. Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging 30: 1-13.
11. Ding S, Shi J, Qian W, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F. 2011. Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging [Epub ahead of print].
12. Dolan PJ, Johnson GV. 2010. The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Dev 13: 595-603.
13. Eckert A, Schulz KL, Rhein V, Götz J. 2010. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol 41: 107-114.
14. Gao L, Tse SW, Conrad C, Andreadis A. 2005. Saitohin, which is nested in the tau locus and confers allele-specific susceptibility to several neurodegenerative diseases, interacts with peroxiredoxin 6. J Biol Chem 280: 39268-39272.
15. Gao L, Wang J, Wang Y, Andreadis A. 2007. SR protein 9G8 modulates splicing of tau exon 10 via its proximal downstream intron, a clustering region for frontotemporal dementia mutations. Mol Cell Neurosci 34: 48-58.
16. Gasparini L, Terni B, Spillantini MG. 2007. Frontotemporal dementia with tau pathology. Neurodegen Dis 4: 236-253.
17. Gendron TF, Petrucelli L. 2009. The role of tau in neurodegeneration. Mol Neurodegener 4: 13-31.
18. Glatz DC, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, Rosenberg C, Hulette C, Jellinger K, Hampel H, Rieder P, Moeller HJ, Andreadis A, Henkel K, Stamm S. 2005. The alternative splicing of tau exon 10 and its regulatory proteins clk2 and tra2-beta1 changes in sporadic Alzheimer's disease. J Neurochem 96: 635-644.
19. Gordon-Weeks PR. 1993. Organization of microtubules in axonal growth cones: A role for microtubule-associated protein MAP1B. J Neurocytol 22: 717-725.
20. Götz J, Ittner LM, Fändrich M, Schonrock N. 2008. Is tau aggregation toxic or protective: A sensible question in the absence of sensitive methods? J Alzheimers Dis 14: 423-429.
21. Hertel KJ. 2008. Combinatorial control of exon recognition. J Biol Chem 283: 1211-1215.
22. Holzer M, Craxton M, Jakes R, Arendt T, Goedert M. 2004. Tau gene (MAPT) sequence variation among primates. Gene 341: 313-322.
23. Ittner LM, Götz J. 2011. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12: 65-72.
24. Jeganathan S, von Bergen M, Brutlach H, Steinhoff HJ, Mandelkow E. 2006. Global hairpin folding of tau in solution. Biochemistry 45: 2283-2293.
25. Jellinger KA. 2009. Recent advances in our understanding of neurodegeneration. J Neural Transm 116: 1111-1162.
26. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA. 2004. Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 13: 3079-3088.
27. Kar A, Fushimi K, Zhou X, Ray P, Shi C, Chen X, Liu Z, Chen S, Wu JY. 2011. RNA Helicase p68 (DDX5) regulates tau exon 10 splicing by modulating a stem-loop structure at the 5′ splice site. Mol Cell Biol 31: 1812-1821.
28. LaFerla FM. 2010. Pathways linking Abeta and tau pathologies. Biochem Soc Trans 38: 993-995.
29. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST. 2009. The amino terminus of tau inhibits kinesin-dependent axonal transport: Implications for filament toxicity. J Neurosci Res 87: 440-451.
30. Lebouvier T, Scales TM, Williamson R, Noble W, Duyckaerts C, Hanger DP, Reynolds CH, Anderton BH, Derkinderen P. 2009. The microtubule-associated protein tau is also phosphorylated on tyrosine. J Alzheimers Dis 18: 1-9.
31. Lee G. 2005. Tau and src family tyrosine kinases. Biochim Biophys Acta 1739: 323-330.
32. Liu F, Gong CX. 2008. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 3: 8-17.
33. Llamusí B, Artero R. 2008. Molecular effects of the CTG repeats in mutant dystrophia myotonica protein kinase gene. Curr Genomics 9: 509-516.
34. Long JC, Cáceres JF. 2009. The SR protein family of splicing factors: Master regulators of gene expression. Biochem J 417: 15-27.
35. Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, Chabot B. 2007. HnRNP proteins and splicing control. Adv Exp Med Biol 623: 123-147.
36. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Jr., Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. 2009. Axonal transport defects in neurodegenerative diseases. J Neurosci 29: 12776-12786.
37. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. 2008. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413-1415.
38. Pennisi E. 2008. 17q21.31: Not your average genomic address. Science 322: 842-845.
39. Pooler AM, Hanger DP. 2010. Functional implications of the association of tau with the plasma membrane. Biochem Soc Trans 38: 1012-1015.
40. Sahara N, Maeda S, Takashima A. 2008. Tau oligomerization: A role for tau aggregation intermediates linked to neurodegeneration. Curr Alzheimer Res 5: 591-598.
41. Sergeant N, Sablonnière B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A. 2001. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.Hum. Mol Genet 10: 2143-2155.
42. Shi J, Zhang T, Zhou C, Chohan MO, Gu X, Wegiel J, Zhou J, Hwang YW, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F. 2008. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem 283: 28660-28669.
43. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA, Soreq H. 2005. Function of alternative splicing. Gene 344: 1-20.
44. Tazi J, Bakkour N, Stamm S. 2009. Alternative splicing and disease. Biochem Biophys Acta 1792: 14-26.
45. Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. 2008. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD study. Neurology 71: 28-34.
46. Wang Z, Burge CB. 2008. Splicing regulation: From a parts list of regulatory elements to an integrated splicing code. RNA 14: 802-813.
47. Wang JZ, Liu F. 2008. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85: 148-175.
48. Wang Y, Gao L, Tse SW, Andreadis A. 2010. Heterogeneous nuclear ribonucleoprotein E3 modestly activates splicing of tau exon 10 via its proximal downstream intron, a hotspot for frontotemporal dementia mutations. Gene 451: 23-31.
49. Wolfe MS. 2009. Tau mutations in neurodegenerative diseases. J Biol Chem 284: 6021-6025.